intestinal fluid

GlyH-101 是一种可渗透入细胞的 CFTR 阻断剂，Ki 为1.4 uM。

Flufenamic acid-d4 is intended for use as an internal standard for the quantification of flufenamic acid by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively). Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner. It inhibits calcium influx induced by fMLP or A23187 in human polymorphonuclear leukocytes (PMN) with IC50 values of 29 and 14 µM, respectively. Flufenamic acid also activates various ion channels, including transient receptor potential canonical 6 (TRPC6) and the large-conductance calcium-activated potassium channel (KCa1.1). It also inhibits various ion channels, including TRPC3 and the cystic fibrosis transmembrane conductance regulator (CFTR). Flufenamic acid (20 mg kg) reduces increases in intestinal fluid secretion and intestinal barrier disruption in mice ......

PAT1inh-B01为选择性SLC26A6抑制剂，抑制PAT1（Cl- HCO3-交换器）介导的阴离子交换（IC50: 350 nM），并阻断小肠液体吸收，适用于小肠分泌不足相关疾病研究。

PAT1inh-A0030 是一种选择性 PAT1 (SLC26A6) 抑制剂 (IC50 = 1.0 μM)。在肠道液体吸收闭环模型中，PAT1inh-A0030 抑制野生型和囊性纤维化 (CF) 小鼠 (CftrdelF508 delF508) 回肠的液体吸收，可用于 CF 相关肠道疾病的研究。

Lubiprostone (hemiketal) (RU-0211 (hemiketal)) 作为CLCN2激活剂，能够选择性地增强氯离子通道2功能。通过促进肠道氯离子的分泌，Lubiprostone (hemiketal) 提高了肠内液体的产生并优化肠蠕动，主要应用于处理慢性特发性便秘及阿片类药物引起的便秘。此外，该化合物也被用于慢性便秘和癌症的相关研究。

Tilifodiolide exerts in vitro and in vivo anti-inflammatory activity and in vivo antinociceptive effects. Tilifodiolide exerted antidiarrheal activity by decreasing the intestinal fluid accumulation and vasorelaxant effects mediated by nitric oxide and cyclic guanosine monophosphate, it also showed anxiolytic and antidepressant effects by the partial involvement of gamma-Aminobutyric acid (GABA) receptors and the possible participation of α2-adrenoreceptors, respectively.